Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Conditions
Interventions
Advate (Low Dose)
Advate (High Dose)
+2 more
Locations
10
United States
University of California Los Angeles Medical Center
Los Angeles, California, United States
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana, United States
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States
Michigan State University
East Lansing, Michigan, United States
Mississippi Center for Advanced Medicine
Madison, Mississippi, United States
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania, United States
Start Date
August 28, 2017
Primary Completion Date
November 12, 2018
Completion Date
November 12, 2018
Last Updated
April 19, 2022
NCT07226206
NCT05987449
NCT04645199
NCT06703606
NCT06702579
NCT03818763
Lead Sponsor
Bioverativ, a Sanofi company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions